2 results
Approved WMORecruiting
2.1 Primary Objectives• Evaluate the safety and tolerability of 2 fixed doses of FRM-0334 (300 and 500 mg daily in 2 sequential periods) over 28 days in subjects with prodromal to moderate FTD-GRN• Assess the PD effects of FRM-0334 on the change…
Approved WMOPending
To evaluate the efficacy and safety of nilotinib in spondyloarthritis